SMO and cancer: Furthermore, these results may explain the failure of colon cancer trials using HH pathway inhibitors, given that it is plausible that the pro-inflammatory responses to SMO-targeting may contribute to the acceleration of cancer progression, forcing the termination of the clinical studies [86,87].